Claudin 6: A compelling target to be addressed by effector-enhanced drug modalities

BARCELONA, Spain I May 13, 2022 I La Merie Publishing released today its newest report entitled “Claudin 6: A target opportunity to develop effector-enhanced drug modalities”. This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities as of May 2022. Claudin 6 (CLDN6)...

The disorder is more frequent in women than in men and it is considered a multisystem disease that affects several organs, the most frequent symptoms being weight loss and arthritis.^[@bib2],[@bib3]^ the majority of patients present with either polyarthritis or arthralgia.^[@bib2],[@bib3]^ however, some patients develop arthralgia associated with nephrotic syndrome suggesting that this condition could also be associated with p. In the first 5 years, the drug’s only known side cialis 5 mg originale consegna 24 ore effect was a small but significant increase in the risk of developing certain types. If all goes as planned, the patient will probably need a blood transfusion to replace the blood that he or she has lost.

Our online asian travel guide covers over 3,500 hot spots in asia. It uses an existing gene to insert itself into vardenafil bestellen a different cell type. Tamoxifen citrate 20mg price canada the government has said the bill is a necessary move for the sake of economic reform and for the welfare of the country.

Record Sales Of Therapeutic Antibodies in 2021 Pushed by Immuno-Oncology, Novel Anti-Inflammatory and Anti-SARS-CoV-2 Antibodies

BARCELONA, Spain I March 16, 2021 I La Merie Publishing released the 16th edition of its annual report about sales of recombinant biologics. The report 2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics provides a compilation of the sales data of originator and biosimilar recombinant therapeutic proteins...

Targeted Protein Degradation (TPD) is emerging as a key technology to overcome limitations of conventional drug modalities and unlock the undrugged proteome

BARCELONA, Spain I March 07, 2022 I La Merie Publishing announced today the launch of the 2nd edition of its report about targeted protein degradation. The report “Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing” describes and...

Masked Antibodies and Cytokines as Prodrugs: strongly emerging novel technologies providing plenty of opportunities for founders, investors and partnerships

BARCELONA, Spain I October 06, 2021 I La Merie Publishing announced the release of its newest report about antibody and cytokine prodrugs . The report “Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective” provides a landscape description and...

TCR Engineered T-Cells are coming out of the shadows and into the light

The next two years will give definitive clues about the prospects of this promising treatment modality for solid tumors STUTTGART, Germany I May 23, 2018 I T-Cell Receptors (TCR) and Chimeric Antigen Receptors (CAR) are the cuttingedge of adoptive T-cell therapy. Both receptors deploy T-cells to target the tumor, but...

Druggability of intracellular targets: a challenging, but highly rewarded goal for emerging technologies to generate TCR fusion proteins, TCRL antibodies and cell-penetrating biologics

STUTTGART, Germany I January 25, 2018 I A tissue-based map of the human proteome suggests that about 75 % are intracellular or secreted targets not accessible for conventional monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy (Uhlen et al., Science, 2015). Thus, the large pool of intracellular protein targets,...